期刊文献+

筛选乳腺癌新辅助化疗敏感指标的临床研究 被引量:6

The study of screening sensitive indexes of predicting the curative effects of neoadjuvant chemotherapy in treatment of breast cancer
下载PDF
导出
摘要 目的探讨新辅助化疗前乳腺癌患者ER、PR、Ki-67、C-erb B-2、VEGF、DBC2表达状态与新辅助化疗疗效的关系。方法选择Ⅱb~Ⅲc期行新辅助化疗的初治乳腺癌患者45例,采用免疫组织化学法检测化疗前及术后ER、PR、Ki-67、C-erb B-2、VEGF、DBC2的表达情况。结果单因素分析发现ER、PR表达阴性及Ki-67、VEGF高表达时,新辅助化疗病理完全缓解率及MP分级4~5级化疗反应比例分别高于ER、PR表达阳性及Ki-67、VEGF低表达时,差异有统计学意义(P<0.05)。结论 ER、PR表达阴性,Ki-67、VEGF高表达对新辅助化疗更敏感,可做为新辅助化疗疗效的预测因子。 Objective To investigate the expressions of ER,PR,Ki-67,C-erb B-2,VEGF,DBC2 before neoadjuvant chemotherapy in patients with breast cancer,and to explore the correlation between their expression levels and curative effects of neoadjuvant chemotherapy( NAC). Methods Forty-five patients with breast cancer at stage Ⅱ b ~ Ⅲ c who received neoadjuvant chemotherapy were enrolled in the study. The expression levels of ER,PR,Ki-67,C-erb B-2,VEGF and DBC2 were detected by immunohistochemistry before and after neoadjuvant chemotherapy. Results The univariate analysis showed that when the expressions of ER and PR were negative and Ki-67 and VEGF were highly expressed,the pathological complete remission rate after neoadjuvant chemotherapy and the proportion of chemotherapy reaction of grade 4 ~ 5( MP classification)were significantly higher than those when the expressions of ER and PR were positive and Ki-67 and VEGF were lowly expressed,respectively( P 〈0. 05). Conclusion The breast cancer patients with negative expressions of ER and PR and high expressions of Ki-67 and VEGF are more sensitive to NAC,thus,which may be regarded as predictive indexes of NAC.
出处 《河北医药》 CAS 2018年第3期356-360,共5页 Hebei Medical Journal
关键词 乳腺癌 新辅助化疗 免疫组化 生物学因子 breast cancer neoadjuvant chemotherapy immunohistochemisty biological factors
  • 相关文献

参考文献1

二级参考文献15

  • 1Siege 1R, Naishadham D, Jemal A. Cancer statistics, 2013 [ J]. CA Cancer Journal for Clinicians,2013,63 ( 1 ) :11-30.
  • 2Enserink M. A push to fight cancer in the developing world [ J ]. Sci- ence,2011,331 (6024) :1548-1550.
  • 3Zhang Y, Liao JM, Zeng SX, et al. p53 downregnlates Down syndrome- associated DYRK1A through miR-1246 [ J ]. EMBO Reports, 2011,12 (8) :811-$17.
  • 4Liao JM,Zhou X,Zhang Y, et al. MiR-12g6: a new link of the p53 family with cancer and Down syndrome [ J ]. Cell Cycle, 2012, 11 (lg) :2624-2630.
  • 5Wang Q,Li D,Li Z,et al. Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen[J]. Oncogene,2011,30(36) :3875-3886.
  • 6Fanning AS , Van Itallie CM, Anderson JM. Zonula occludens-1 and-2 regulate apical cell structure and the zonula adherens cytoskeleton in polarized epithelia[ J]. Mol Biol Cell,2012,23 (4) :577-590.
  • 7Ni SH, Xu LQ, Huang JF, et al. Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer [ J ]. Int J Clin Exp Patho1,2013,6 ( 12 ) :2887-2895.
  • 8Taavi Pall, Anne Pink, Lagle Kasak, et al. Soluble CD44 Interacts with Intermediate Filament Protein Vimentin on Endothelial Cell Sur- face[J]. PLoS One,2011,6(12) :e29305.
  • 9Kidd ME, Shumaker DK, Ridge KM. The Role of Vimentin Intermedi- ate Filaments in the Progression of Lung Cancer [ J ]. J Respir Cell Mol Biol,2014,50( 1 ) :1-6.
  • 10Barrire G1,Tartary M, Rigaud M. Metformin:a rising star to fight the epithelial mesenchymal transition in oncology [ J ]. Anticancer Agents Med Chem,2013,13(2) :333-340.

共引文献2

同被引文献82

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部